Affiliation:
1. Department of Restorative Dentistry
2. Department of Oral Medicine and Pathology, School of Dental Science and Dublin Dental Hospital, Trinity College, University of Dublin, Dublin 2, Ireland
Abstract
ABSTRACT
Candida dubliniensis
is a recently described
Candida
species associated with oral candidiasis in human immunodeficiency virus (HIV)-infected patients and patients with AIDS. The majority of
C. dubliniensis
clinical isolates tested to date are susceptible to the commonly used antifungal drugs, including fluconazole, ketoconazole, itraconazole, and amphotericin B. However, the appearance of fluconazole-resistant
C. dubliniensis
strains in this patient group is increasing. Histatins are a family of basic histidine-rich proteins present in human saliva which have therapeutic potential in the treatment of oral candidiasis. The mechanism of action of histatin is distinct from that of commonly used azole and polyene drugs. Characterization of the antifungal activity of histatin has mainly been carried out using
C. albicans
but it is also effective in killing
C. glabrata
and
C. krusei
. Here we report that
C. dubliniensis
is also susceptible to killing by histatin 3. The concentration of histatin 3 giving 50% killing (the IC
50
value) ranged from 0.043 to 0.196 mg/ml among different strains of
C. dubliniensis
. The least-susceptible
C. dubliniensis
strain, P9224, was found to internalize histatin at a lower rate than the
C. albicans
reference strain CA132A. The dissociation constant (
K
d
) for the least-susceptible strain (
C. dubliniensis
9224) was ninefold higher than that for the
C. albicans
reference strain. These results suggest that histatin 3 may have potential as an effective antifungal agent, particularly in the treatment of oral candidiasis in HIV-infected patients and patients with AIDS in which resistance to the commonly used antifungal drug fluconazole has emerged.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference39 articles.
1. Beck-Sague, C. M., W. R. Jarwis, et al. 1993. Secular trends in the epidemiology of nosocomial fungal infection in the United States, 1980-1990. J. Infect. Dis.167:1247-1251.
2. Bercier, J. G., I. Al-Hashimi, N. Haghighat, T. D. Rees, and F. G. Oppenheim. 1999. Salivary histatins in patients with recurrent oral candidiasis J. Oral Pathol. Med.28:26-29.
3. Boyle, B. M., D. J. Sullivan, C. Forkin, F. Mulcahy, C. T., Keane, and D. C. Coleman. 2002. Candida dubliniensis candidaemia in an HIV-positive patient in Ireland. Int. J. STD AIDS13:55-57.
4. Brandt, M. E., L. H. Harrison, M. Pass, A. N. Sofair, S. Huie, R. K. Li, C. J. Morrison, D. W. Warnock, and R. A. Hajjeh. 2000. Candida dubliniensis fungemia: the first four cases in North America. Emerg. Infect. Dis.6:46-49.
5. Calderone, R. A., and W. A. Fonzi. 2001. Virulence factors of Candida albicans.Trends Microbiol.9:327-335.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献